On March 31, 2022, Mary Ann Gray, Ph.D., informed the board of directors of Sarepta Therapeutics, Inc. that she has elected to not stand for re-election and will complete her term on the board at the conclusion of the company's 2022 annual meeting of stockholders. Dr. Gray's decision to not stand for re-election was not because of a disagreement with the company on any matter relating to the Company's operations, policies, or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
158 USD | +0.03% |
|
+27.94% | +63.85% |
06-26 | Monetary policy is getting even more confusing | ![]() |
06-26 | Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172 | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.85% | 14.93B | |
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+4.49% | 13.52B | |
+116.20% | 10.79B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta Therapeutics, Inc. Announces Not Stand for Re-Election of Mary Ann Gray as Board of Director